MX2022014466A - Combinacion de acetil leucina y 4-aminopiridina o acetazolamida para tratar la ataxia. - Google Patents

Combinacion de acetil leucina y 4-aminopiridina o acetazolamida para tratar la ataxia.

Info

Publication number
MX2022014466A
MX2022014466A MX2022014466A MX2022014466A MX2022014466A MX 2022014466 A MX2022014466 A MX 2022014466A MX 2022014466 A MX2022014466 A MX 2022014466A MX 2022014466 A MX2022014466 A MX 2022014466A MX 2022014466 A MX2022014466 A MX 2022014466A
Authority
MX
Mexico
Prior art keywords
combination
acetazolamide
aminopyridine
leucine
acetyl
Prior art date
Application number
MX2022014466A
Other languages
English (en)
Spanish (es)
Inventor
Michael Strupp
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of MX2022014466A publication Critical patent/MX2022014466A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2022014466A 2020-05-22 2021-05-20 Combinacion de acetil leucina y 4-aminopiridina o acetazolamida para tratar la ataxia. MX2022014466A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063028760P 2020-05-22 2020-05-22
PCT/IB2021/054399 WO2021234642A1 (en) 2020-05-22 2021-05-20 The combination of acetyl leucine and 4-aminopyridine or acetazolamide for treating ataxia

Publications (1)

Publication Number Publication Date
MX2022014466A true MX2022014466A (es) 2022-12-13

Family

ID=76181172

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014466A MX2022014466A (es) 2020-05-22 2021-05-20 Combinacion de acetil leucina y 4-aminopiridina o acetazolamida para tratar la ataxia.

Country Status (7)

Country Link
US (1) US20230201150A1 (enExample)
EP (1) EP4153161A1 (enExample)
JP (1) JP2023526517A (enExample)
KR (1) KR20230015433A (enExample)
CA (1) CA3179105A1 (enExample)
MX (1) MX2022014466A (enExample)
WO (1) WO2021234642A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120157593A (zh) * 2018-12-06 2025-06-17 内在生物技术有限公司 乙酰基-亮氨酸的氘代类似物
MD3989962T2 (ro) 2019-06-28 2025-12-31 Intrabio Ltd Gb Terapie combinată cu acetil-leucină și miglustat pentru tratamentul unei boli de depozitare lizozomală
WO2021144720A1 (en) 2020-01-13 2021-07-22 Intrabio Ltd Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers
TW202604470A (zh) * 2024-06-20 2026-02-01 美商音特拉拜歐公司 乙醯白胺酸用於治療神經發育障礙

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
JP2009269856A (ja) * 2008-05-07 2009-11-19 Nobufumi Ono 異常行動防止薬及びこれを含むインフルエンザ治療薬
CA2803166C (en) 2010-06-25 2023-03-07 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
EP2667869A1 (en) * 2011-01-28 2013-12-04 Acorda Therapeutics, Inc. Use of potassium channel blockers to treat cerebral palsy
TN2016000259A1 (en) * 2016-06-27 2017-10-06 Rekik Raouf Salbutamol (albuterol) eye protective medicament.
TN2019000033A1 (fr) * 2016-08-11 2020-07-15 Intrabio Ltd Agents thérapeutiques pour maladies neurodégénératives
US10485790B1 (en) * 2018-09-13 2019-11-26 Syneurx International (Taiwan) Corp. Salts of cycloserine compounds and applications thereof
WO2021048431A1 (en) * 2019-09-12 2021-03-18 Amabiotics Compounds for treating ataxia

Also Published As

Publication number Publication date
KR20230015433A (ko) 2023-01-31
WO2021234642A1 (en) 2021-11-25
EP4153161A1 (en) 2023-03-29
JP2023526517A (ja) 2023-06-21
CA3179105A1 (en) 2021-11-25
US20230201150A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
ZA202206806B (en) Benzooxazole derivatives as immunomodulators
ZA202007007B (en) Mcl-1 inhibitors
ZA202001717B (en) Compounds, salts thereof and methods for treatment of diseases
PH12018501226A1 (en) Methods for treating huntingtons disease
PH12019502379A1 (en) Pd-1/pd-l1 inhibitors
CL2018000108A1 (es) Moléculas de anticuerpo que se unen a cd22
MY201925A (en) Macrocyclic compounds and uses thereof
MX2019002750A (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
AU2018278311A1 (en) IRE1 small molecule inhibitors
SG11201901061QA (en) Heterocyclic compound
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
AR101740A1 (es) Terapia de combinación y composiciones
JOP20210050A1 (ar) معدلات تعبير pnpla3
MX391017B (es) Activacion de linfocitos que infiltran la medula en condiciones hipoxicas alternando con normoxicas.
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
MX2016013600A (es) Método para tratar adenocarcinoma de pulmón.
MX389692B (es) Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc.
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
TR201811308T4 (tr) Kanser kok hücrelerini azaltan anti-emp2 tedavisi.
CL2019002325A1 (es) Combinaciones farmacéuticas para tratar cáncer.
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
PH12018502381A1 (en) Dihydrotestosterone and dihydrotestosterone derivatives and promoters in the treatment of cancer